Literature DB >> 16675345

Toll-like receptor 2 ligands inhibit TH2 responses to mite allergen.

Rebecca C Taylor1, Peter Richmond, John W Upham.   

Abstract

BACKGROUND: There is intense interest in the interaction between microbial compounds and allergy. Although Toll-like receptor (TLR)-2 ligands derived from Gram-positive bacteria alter allergic sensitization in animal models, it is not clear what effect TLR2 ligands have on allergen-specific T-cell memory in human beings.
OBJECTIVE: To determine whether in vitro exposure to TLR2 ligands modifies the immune response to house dust mite allergen (HDM).
METHODS: Blood mononuclear cells were obtained from individuals both allergic (n = 23) and not allergic (n = 22) to HDM, and stimulated with HDM in the presence or absence of TLR2 ligands.
RESULTS: In subjects allergic to HDM, IL-5 and IL-13 responses to HDM were inhibited by heat-killed Staphylococcus aureus, staphylococcal lipoteichoic acid, and the synthetic lipoprotein Pam3CSK4 (P < .005; all stimuli). Although the whole staphylococcal bacteria increased IFN-gamma responses, the purified TLR2 ligands lipoteichoic acid and Pam3CSK4 inhibited HDM-specific IFN-gamma synthesis. In contrast, TLR2 ligands had minimal effects on responses to HDM in subjects without allergy. TLR2 ligands induced upregulation of HLA-DR expression but did not inhibit antigen uptake or processing by antigen-presenting cells.
CONCLUSION: Toll-like receptor 2 ligands inhibit allergen-specific T(H)2 responses in sensitized individuals. This effect appears to be mediated by the actions of TLR2 ligands on antigen-presenting cells, and at least for the purified TLR2 ligands does not involve the induction of a strong T(H)1 immune response. CLINICAL IMPLICATIONS: These findings provide an impetus for further preclinical studies examining the potential use of TLR2 ligands in allergic disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675345     DOI: 10.1016/j.jaci.2006.02.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  24 in total

Review 1.  Dangerous allergens: why some allergens are bad actors.

Authors:  Steve N Georas; Fariba Rezaee; Laurie Lerner; Lisa Beck
Journal:  Curr Allergy Asthma Rep       Date:  2010-03       Impact factor: 4.806

Review 2.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 3.  Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets.

Authors:  Vikas Mishra; Jaspreet Banga; Patricia Silveyra
Journal:  Pharmacol Ther       Date:  2017-08-23       Impact factor: 12.310

4.  Toll-like receptors 2, 3 and 4 and thymic stromal lymphopoietin expression in fatal asthma.

Authors:  D S Ferreira; R Annoni; L F F Silva; M Buttignol; A B G Santos; M C R Medeiros; L N S Andrade; C Y Yick; P J Sterk; J L M Sampaio; M Dolhnikoff; S E Wenzel; T Mauad
Journal:  Clin Exp Allergy       Date:  2012-10       Impact factor: 5.018

5.  A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice.

Authors:  Kristen Page; John R Ledford; Ping Zhou; Marsha Wills-Karp
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

6.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

7.  A synthetic Toll-like receptor 2 ligand decreases allergic immune responses in a mouse rhinitis model sensitized to mite allergen.

Authors:  Cheng Zhou; Xiao-Dong Kang; Zhi Chen
Journal:  J Zhejiang Univ Sci B       Date:  2008-04       Impact factor: 3.066

Review 8.  Current immunological approaches for management of allergic rhinitis and bronchial asthma.

Authors:  Deepsikha Srivastava; Naveen Arora; Bhanu Pratap Singh
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

9.  Toll-like receptor 2 agonists inhibit human fibrocyte differentiation.

Authors:  Anu S Maharjan; Darrell Pilling; Richard H Gomer
Journal:  Fibrogenesis Tissue Repair       Date:  2010-11-24

10.  DC priming by M. vaccae inhibits Th2 responses in contrast to specific TLR2 priming and is associated with selective activation of the CREB pathway.

Authors:  Nina Le Bert; Benjamin M Chain; Graham Rook; Mahdad Noursadeghi
Journal:  PLoS One       Date:  2011-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.